Celecoxib and Myrtol: A Novel Therapy for Recurrent Appendiceal Mucinous Neoplasms With Extensive Peritoneal Dissemination.
Administration, Oral
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Appendiceal Neoplasms
/ drug therapy
Carcinoembryonic Antigen
/ analysis
Celecoxib
/ administration & dosage
Cytoreduction Surgical Procedures
Drug Combinations
Female
GPI-Linked Proteins
/ analysis
Humans
Male
Middle Aged
Monoterpenes
/ administration & dosage
Neoplasm Recurrence, Local
/ therapy
Peritoneal Neoplasms
/ drug therapy
Retrospective Studies
Treatment Outcome
Journal
American journal of clinical oncology
ISSN: 1537-453X
Titre abrégé: Am J Clin Oncol
Pays: United States
ID NLM: 8207754
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
pubmed:
4
12
2021
medline:
15
2
2022
entrez:
3
12
2021
Statut:
ppublish
Résumé
Unresectable appendiceal mucinous neoplasms (AMNs) with extensive peritoneal dissemination cause significant morbidity and have limited treatment options. We evaluated a novel combination of Celecoxib and Myrtol in treating such AMNs. Patients with recurrent AMNs with extensive peritoneal disease treated with a daily regimen of 200 mg Celecoxib and 1200 mg Myrtol Standardized were included. Progression-free survival (PFS) and overall survival (OS) were calculated, and carcinoembryonic antigen (CEA) trends were compared pretreatment and post-treatment in terms of percentage change. Thirteen patients with extensive, recurrent disease (median peritoneal carcinomatosis index of 36) were included between 2017 and 2020. The median age was 63 years (interquartile range: 55 to 67) and 7 (54%) were male. A total of 85% had undergone prior cytoreductive surgery while 15% underwent cytoreductive surgery >2 times. 54% had received multiple cycles of systemic chemotherapy before starting Celecoxib-Myrtol. After a median follow-up of 8 months, median PFS and OS were 16 months (interquartile range: 5 to 17) and 27 months, respectively. Nine (69.2%) showed improvement in CEA values 3 months after treatment compared with 3-month pretreatment CEA trends. None had adverse events attributable to Celecoxib-Myrtol. Our feasibility study suggests that a regimen of Celecoxib-Myrtol is well tolerated and may prolong PFS and OS in patients with recurrent AMNs with peritoneal spread.
Sections du résumé
BACKGROUND
Unresectable appendiceal mucinous neoplasms (AMNs) with extensive peritoneal dissemination cause significant morbidity and have limited treatment options. We evaluated a novel combination of Celecoxib and Myrtol in treating such AMNs.
METHODS
Patients with recurrent AMNs with extensive peritoneal disease treated with a daily regimen of 200 mg Celecoxib and 1200 mg Myrtol Standardized were included. Progression-free survival (PFS) and overall survival (OS) were calculated, and carcinoembryonic antigen (CEA) trends were compared pretreatment and post-treatment in terms of percentage change.
RESULTS
Thirteen patients with extensive, recurrent disease (median peritoneal carcinomatosis index of 36) were included between 2017 and 2020. The median age was 63 years (interquartile range: 55 to 67) and 7 (54%) were male. A total of 85% had undergone prior cytoreductive surgery while 15% underwent cytoreductive surgery >2 times. 54% had received multiple cycles of systemic chemotherapy before starting Celecoxib-Myrtol. After a median follow-up of 8 months, median PFS and OS were 16 months (interquartile range: 5 to 17) and 27 months, respectively. Nine (69.2%) showed improvement in CEA values 3 months after treatment compared with 3-month pretreatment CEA trends. None had adverse events attributable to Celecoxib-Myrtol.
CONCLUSIONS
Our feasibility study suggests that a regimen of Celecoxib-Myrtol is well tolerated and may prolong PFS and OS in patients with recurrent AMNs with peritoneal spread.
Identifiants
pubmed: 34857698
doi: 10.1097/COC.0000000000000878
pii: 00000421-202201000-00002
doi:
Substances chimiques
CEACAM5 protein, human
0
Carcinoembryonic Antigen
0
Drug Combinations
0
GPI-Linked Proteins
0
Monoterpenes
0
myrtol
8002-55-9
Celecoxib
JCX84Q7J1L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-13Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Shaib WL, Martin LK, Choi M, et al. Hyperthermic intraperitoneal chemotherapy following cytoreductive surgery improves outcome in patients with primary appendiceal mucinous adenocarcinoma: a pooled analysis from three tertiary care centers. Oncologist. 2015;20:907–914.
Austin F, Mavanur A, Sathaiah M, et al. Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol. 2012;19:1386–1393.
Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–2456.
Yan TD, Black D, Savady R, et al. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14:484–492.
Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221:124–132.
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–374.
Overman MJ, Fournier K, Hu C, et al. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. Ann Surg. 2013;257:1072–1078.
Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219:112–119.
Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei : clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15:526–534.
Roma K, Baldwin M, Sedmak D, et al. Late stage diagnosis of mucinous adenocarcinoma of the appendix: a case report of an unusual tumor with a rare presentation. BMC Gastroenterol. 2020;20:281.
Paul Olson TJ, Pinkerton C, Brasel KJ, et al. Palliative surgery for malignant bowel obstruction from carcinomatosis. JAMA Surg. 2014;149:383–392.
Kim S-H, Song S-H, Kim S-G, et al. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol. 2004;130:551–560.
Pang R-P, Zhou J-G, Zeng Z-R, et al. Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3β/NAG-1 pathway. Cancer Lett. 2007;251:268–277.
Raut CP, Nawrocki S, Lashinger LM, et al. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther. 2004;3:1217–1224.
Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–1952.
Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885–895.
Toloczko-Iwaniuk N, Dziemianczyk-Pakiela D, Nowaszewska BK, et al. Celecoxib in cancer therapy and prevention—review. Curr Drug Targets. 2019;20:302–315.
Raghav KPS, Shetty AV, Kazmi SMA, et al. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013;18:1270–1277.
Choudry HA, Mavanur A, O'Malley ME, et al. Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei. Ann Surg Oncol. 2012;19:1402–1409.
Green DE, Jayakrishnan TT, Hwang M, et al. Immunohistochemistry—microarray analysis of patients with peritoneal metastases of appendiceal or colorectal origin. Front Surg. 2015;1:50.
Begrow F, Böckenholt C, Ehmen M, et al. Effect of myrtol standardized and other substances on the respiratory tract: ciliary beat frequency and mucociliary clearance as parameters. Adv Ther. 2012;29:350–358.
Dilly A, Honick BD, Lee YJ, et al. Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors. Cancer Med. 2020;9:1753–1767.
Semino-Mora C, Liu H, McAvoy T, et al. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. Ann Surg Oncol. 2008;15:1414–1423.
Semino-Mora C, Testerman TL, Liu H, et al. Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects beta-catenin distribution. Clin Cancer Res. 2013;19:3966–3976.
Gilbreath JJ, Semino-Mora C, Friedline CJ, et al. A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei. Orphanet J Rare Dis. 2013;8:105.
Pillai K, Akhter J, Chua TC, et al. Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei. Invest New Drugs. 2012;30:2080–2086.
Valle SJ, Akhter J, Mekkawy AH, et al. A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: a phase I first in man study. Eur J Surg Oncol. 2021;47:115–122.
Green N, Gancedo H, Smith R, et al. Pseudomyxoma peritonei—nonoperative management and biochemical findings. A case report. Cancer. 1975;36:1834–1837.
Piver MS, Lele SB, Patsner B. Pseudomyxoma peritonei: possible prevention of mucinous ascites by peritoneal lavage. Obstet Gynecol. 1984;64:95S–96S.
Machado MA, Rodrigues JG, Laurino RM, et al. Conservative treatment of pseudomyxoma peritonei. Rev Hosp Clin Fac Med Sao Paulo. 1993;48:301–304.
Shapiro JF, Chase JL, Wolff RA, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin. Cancer. 2010;116:316–322.